Home/Pipeline/INI-4001

INI-4001

Oncology

Phase 1Active

Key Facts

Indication

Oncology

Phase

Phase 1

Status

Active

Company

Inimmune

About Inimmune

Inimmune is a private, clinical-stage biotech developing disease-modifying immunotherapies based on innate immune system modulation. Its lead programs are two clinical-stage TLR agonists: INI-2004 for allergic rhinitis (Phase 2) and INI-4001 for oncology (Phase 1). The company also has a robust pre-clinical pipeline focused on novel adjuvants and innate immune agonists/antagonists, supported by strategic academic and industry collaborations. Inimmune is pre-revenue and positioned in the high-potential but competitive immunotherapy and vaccine adjuvant markets.

View full company profile

Therapeutic Areas

Allergy Oncology Infectious Disease Vaccine Adjuvants

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active